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Genetic and epigenetic methylation defects and implication
of the ERMN gene in autism spectrum disorders
A Homs1,2,3,8, M Codina-Solà1,2,3,8, B Rodríguez-Santiago4, CM Villanueva5,6, D Monk7, I Cuscó1,2,3 and LA Pérez-Jurado1,2,3
Autism spectrum disorders (ASD) are highly heritable and genetically complex conditions. Although highly penetrant mutations in
multiple genes have been identified, they account for the etiology of o1/3 of cases. There is also strong evidence for
environmental contribution to ASD, which can be mediated by still poorly explored epigenetic modifications. We searched for
methylation changes on blood DNA of 53 male ASD patients and 757 healthy controls using a methylomic array (450K Illumina),
correlated the variants with transcriptional alterations in blood RNAseq data, and performed a case–control association study of the
relevant findings in a larger cohort (394 cases and 500 controls). We found 700 differentially methylated CpGs, most of them
hypomethylated in the ASD group (83.9%), with cis-acting expression changes at 7.6% of locations. Relevant findings included: (1)
hypomethylation caused by rare genetic variants (meSNVs) at six loci (ERMN, USP24, METTL21C, PDE10A, STX16 and DBT) significantly
associated with ASD (q-value o0.05); and (2) clustered epimutations associated to transcriptional changes in single-ASD patients
(n= 4). All meSNVs and clustered epimutations were inherited from unaffected parents. Resequencing of the top candidate genes
also revealed a significant load of deleterious mutations affecting ERMN in ASD compared with controls. Our data indicate that
inherited methylation alterations detectable in blood DNA, due to either genetic or epigenetic defects, can affect gene expression
and contribute to ASD susceptibility most likely in an additive manner, and implicate ERMN as a novel ASD gene.
Translational Psychiatry (2016) 6, e855; doi:10.1038/tp.2016.120; published online 12 July 2016
INTRODUCTION
Autism spectrum disorders (ASD; OMIM 209850) are a group of
early-onset neurodevelopmental disorders diagnosed on the basis
of two symptom areas: social communication impairments, and
restricted repetitive behaviors, interests or activities (DSM-V). The
currently estimated prevalence of ASD is 1/42 males and 1/189
females aged 8 years, after a documented prevalence increase
during the past two decades.1 There is strong evidence for a
genetic etiology of ASD with heritability ranging from 50 to
90%.2,3 However, despite remarkable advances driven by genetics
and genomics leading to the identification of single-gene
mutations, copy-number changes and double hit models, the
etiology of around 70% of ASD cases still remains unknown.4,5 This
relatively poor detection rate could be explained in part by the
high phenotypic and genetic heterogeneity of ASD with multiple
inheritance models, including monogenic, oligogenic and poly-
genic with gene–environment interactions.6–8 In addition, most
genomic studies to date have focused on the analysis of sequence
and copy-number changes in the coding part of the genome,
therefore, missing putative epimutations and other changes
located elsewhere in the genome.
Epigenetics comprises DNA methylation, long non-coding
RNA and histone post-translational modifications, which act as
regulatory mechanisms of gene expression. Epigenetic aberrations
have been associated with a wide range of diseases including
ASD.9,10 Several single-gene disorders commonly associated with
autism (that is, Fragile-X11 and Rett syndromes12 show multiple
epigenetic deregulations, and recurrent genomic alterations in
chromosomal regions subjected to imprinting (chr7q, 15q (ref.
13,14)) commonly manifest as ASD. Other epigenetic defects
secondary to mutations in genes such as UBE3A15 and OXCTR,16
as well as altered CpG methylation in genes such as RORA, BCL1
(ref. 17) and EN-2,18 have also been implicated in autism.
Therefore, methylation and imprinting alterations associated or
not to genetic anomalies, may be responsible for additional cases
of ASD. Although epigenetics is still a poorly explored field in ASD,
the current genome-wide technologies permit to assess DNA
methylome in the available tissues. To date, several small-size
case–control studies have addressed methylomic abnormalities in
ASD searching for differences in twin pairs discordant for the
disease on cell line or blood DNA,17,19 investigating DNA from
different brain regions,20,21 or looking for effects of advanced
maternal age on buccal epithelium as a surrogate of ectodermal
cells.22 Methylation analyses of promoter regions of genes in
blood DNA failed to detect relevant changes in an initial study
(analyzing 1505 regions in 70 patients),23 while reporting
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hypermethylation at ENO2 in 14.5% ASD cases (analyzing 16,000
regions in 131 patients).24
In this study we aimed to identify methylation aberrations in
blood DNA of a cohort of ASD patients in a search for testable
epigenetic biomarkers contributing to ASD etiology. Functional
consequences were analyzed by RNAseq of blood RNA, integrat-
ing the analysis of epigenetic variants and their transcriptional
consequences. Finally, we performed a case–control study of the
resulting rare variants using an independent and larger ASD
sample in order to increase the power and significance of the
associations, as well as a screening for mutations affecting the
coding sequence in the previously identified genes.
MATERIALS AND METHODS
Study population
We selected 53 unrelated idiopathic ASD male patients, aged from 2 to 14
years (Supplementary Table 1) and referred from several hospitals of the
Spanish Health System. All individuals had a diagnosis of ASD based on
clinical and psychological evaluations (DSM-IV and ADI-R test). Genetic
and biochemical testing for comorbid conditions (Fragile-X and some
metabolic disorders), and molecular karyotyping (aCGH or SNP array) were
negative in all cases. The study was approved by the ethical committee of
the centers involved (CEIC-Parc Salut Mar), and written informed consent
was obtained from the parents or legal tutors.
Healthy controls consisted of 10 age-matched Spanish male children
analyzed simultaneously. Extraction of DNA and RNA was performed from
peripheral blood with the Blood DNA extraction kit (Qiagen, Hilden,
Germany), and RNA was isolated from lymphocytes using a ficoll density-
gradient (STEMCELL Technologies, Vancouver, BC, Canada), according to
the manufacturer’s instructions.
Additional methylation data from 91 controls (males of a wide age
range) were obtained from the Center for Research in Environmental
Epidemiology (CREAL) and the Bellvitge Institute for Biomedical Research
(IDIBELL),25,26 as well as from 656 controls (males and females of European
ancestry aged from 19 to 101 years) available through GEO (GSE40279). All
757 control samples were obtained from whole blood, except for 5 from
cord blood.
In addition, DNA methylation data (blood, 415 ASD and 405 healthy
siblings, males, 6 to 25 years old) obtained with the HumanMethylation27
platform (Illumina, San Diego, CA, USA) were downloaded from dbGAP
database (accession, phs000619) and probes shared by both platforms
were compared.
Methylomic analyses
The DNA was bisulfite converted and hybridized onto Illumina Human-
Methylation450K BeadChips (Illumina) at the Spanish National Genotyping
Centre (Barcelona, Spain), according to the manufacturer’s protocol.
Samples were placed randomly through the chips and a technical replicate
was included in each chip. Raw data were obtained with Genome Studio
(Illumina; v1.8) and quality controls included technical replicates correla-
tion, detection P-value filtering and a bisulfite conversion control. The
obtained correlation Pearson’s mean coefficient values were over 0.903
and the Spearman’s coefficient (rho) over 0.962. Detection P-value was
filtered removing probes with P-values over 0.01 and sample bisulfite
conversion passed the intensity threshold of 4000 as indicated in
manufacturer’s instructions.
We obtained the beta-values for each CpG, ranging from 0 (unmethy-
lated) to 1 (completely methylated). Simple scaling normalization was
applied using the HumMeth27QCReport27 and LUMI28 packages in R.
Differential methylation (DM) analyses were performed using Limma R
Package,29 applying eBayes and linear BH-FDR adjustment; q-value was set
at 0.01. Probes with low-quality detection signal in 45% of the samples,
with cross-reactive hybridization,30 or harboring known single-nucleotide
polymorphisms (SNPs; minor allele frequency (MAF)40.005) within the
CpG±5nt were removed (dbSNPv137.2 and CEU 1000-Genomes data-
bases). We used two different approaches to perform DM analyses: we first
compared the ASD group versus the control group, and then, based on the
assumption that genetic alterations in ASD are highly heterogeneous, we
compared each patient individually versus the control group. Following
the individual approach, we curated the results discarding differentially
methylated CpGs (DMCpGs) altered in any of the control samples, and
those with values below the absolute methylation difference threshold
(Delta Beta value⩾ |1.8|, representing 18% of difference). We prioritized
probes showing methylation-status changes as previously reported,31
being the hypomethylated status with beta-values o0.3, hypermethylated
with beta values 40.7 and intermediate beta in the 0.3–0.7 range. After
the first DM analysis, we performed a second DM analysis including new
healthy control data from an epidemiology study (n= 91, Spanish, males,
wide age range), applying the same statistical analysis and filtering criteria,
except for a less-strict fold change (under 1.5 or 15%). Finally, we
compared the resulting DMCpGs with a publicly available control data set
(GSE40279; n=656 Hispanic and CEU, males and females, wide age range)
and discarded probes altered in this control set with a frequency 40.005,
considered as relatively common epigenetic variants. We obtained
DMCpGs and differentially methylated regions (DMRs). We defined DMRs
as regions with more than one significant DMCpGs close to each other
(using our strict filter of significant difference 418% at each DMCpG). We
also used the COMB-P32 algorithm to detect more subtle methylation
changes in selected windows of 1000 kb and weighted for 50-bp windows
with a nominal P-value o0.01. Manhattan clustering and principal
component analyses were performed using R.
We also performed subset-quantile within array normalization (SWAN) to
correct type1/type2 errors using minfi tool,33 considering an absolute
methylation difference of 7% as previous studies.20,22 Then, the same
pipeline as above was applied to define the final DMCpGs.
DMCpGs validation
We performed genetic and epigenetic validations of selected altered
DMCpGs. Parental samples of ASD probands were also analyzed. The same
DNA samples were subjected to PCR amplification and Sanger sequencing
to analyze the sequence, and to pyrosequencing and BS-PCR direct
sequencing34 to analyze the methylation levels quantitatively or qualita-
tively. Pyrosequencing analyses were performed using PyroMark Q96
(Qiagen, Hilden, Germany) following the manufacturer’s instructions and
the results were analyzed with the software provided. Primer sequences
for pyrosequencing are available upon request. Pyrosequencing was also
used to replicate the analysis in additional samples. Methylation was also
assessed qualitatively by BS-PCR direct sequencing.34 Primers were
designed with Methyl Primer Express v.1. Software (Applied Biosystems,
Carlsbad, CA, USA) and PCR conditions are available on request.
Analysis of cis-acting elements on DMRs
We searched for putative genetic variants in the flanking intervals of the
DMRs. We designed primers at both sides of the DMRs (including ~ 1 kb in
each side), and performed Sanger sequencing of the PCR amplified
products on specific samples. We also used multiple-ligation probe-
amplification (MLPA) with probes located next to the DMCpGs on these
regions using standard protocols and analytical methods. Primers and
probes were designed as explained above and are available upon request.
Large-scale genotyping
In order to define a putative association of the identified rare variants in
ASD patients, we genotyped 32 rare SNVs (Supplementary Table 2) in an
additional set of 394 ASD samples (Spanish and ECACC collection) and 500
Spanish controls by Sequenom (San Diego, CA, USA). We used 250 ng of
DNA to perform the Sequenom assay, which was conducted at Universitat
de Valencia (Valencia, Spain). To compute the statistical association we
included all the data (450K, 27k and Sequenom) and compared allelic
frequencies. Fisher’s exact test and correction by false discovery rate (FDR)
were performed using R (fisher.test function and q-value35).
RNA sequencing
To identify the functional consequences of methylation alterations we
performed an RNAseq study in 29 out of the 53 studied samples, from
which we obtained good quality RNA from blood (RIN47). The RNA library
was prepared and sequenced (paired-end 100-bp reads) using Illumina
HiSeq 2000 (Illumina) and sequence reads aligned (build hg37) using
TopHat36 and Bowtie.37 Expression was quantified by htseqcount in
Conditional Quantile Normalization counts.38 Data were corrected for
batch effect by Combat algorithm (SVA package R).39 We assessed
case–control differential expression of the genes flanking 50 kb upstream
and downstream the DMCpG, distance used in similar studies.40–42
We selected altered genes by Z-score, selecting Z-scores over 2
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(P-value o0.05) or 1.5 if two genes were altered in the same region, as
recommended in expression analysis.43
Targeted NGS sequencing
The coding region of five selected genes (ERMN, STX16, SMG7-AS1, PIK3CD
and ZCCHC9) was included in a targeted resequencing panel analyzing 279
additional idiopathic ASD cases and 105 controls. Samples were
fragmented and processed with the TruSeq DNA Sample Preparation kit
(Illumina). The libraries were captured by the NimbleGen SeqCap EZ
custom Library (Hofman-La Roche, Basel, Switzerland). Quality control was
assessed using FastQC tool,44 adapter sequences were trimmed using Trim
Galore45 and mapping was performed using BWA.46 GATK47 was used for
variant calling and Annovar48 for functional annotation. Rare mutations
predicted deleterious (loss of function or missense predicted damaging
with the CONDEL program49) were selected. We also analyzed exome data
of ASD patients available from dbGAP (accession= phs000482.v1.p1 and
phs000298.v1.p1; n=931) in order to define the number of deleterious
mutations in selected genes. To define whether the burden of deleterious
mutations is higher in ASD, we use exome data from controls in the EXAC
database,50 and compared the mutational load in cases and controls
(Fisher’s test FDR corrected).
Gene ontology analysis
We searched for enriched pathways in DAVIDGo database,51 and for over-
represented functions using CPDB52 for all the genes associated to the
DMCpGs, as well as for the subset of genes with significant association and
located in the DMRs.
RESULTS
Methylation alterations in blood DNA of ASD
Clustering and principal component analyses showed a random
distribution of the methylation data from patients and controls
with no common patterns or systemic differences between groups
independently of the normalization method applied (Supplemen-
tary Figures 1 and 2). A similar result was obtained in the
differential methylation analysis comparing cases with controls as
groups, with no significant differentially methylated CpG (DMCpGs)
identified (q-value o0.01).
In order to detect rare methylation defects, we compared each
individual ASD patient with the age- and gender-matched control
group (n= 10). After assessing differential methylation with the
additional control sets with stringent filtering, we identified 700
DMCpGs present in ASD samples (4 to 33 per sample; Figure 1,
and Supplementary Table 3). We observed a high concordance
between the two normalization methods (93% of the DMCpGs
identified). Only 34 additional DMCpGs were found with minfi
(Supplementary Table 4). Therefore, the results were not affected
by the normalization approaches. To define the consistency of the
identified DMCpGs, we performed sequencing validation on the
same DNA samples at 98 sites, including 85 isolated CpGs and 13
plausible DMRs. The validation rate, conceived as true genetic or
epigenetic variants, was 85% (84/98), 78 sites corresponding to
genetic alterations (meSNVs) and 5 to epigenetic modifications in
the DMRs.
Most of the 700 DMCpGs (587; 83.9%) in ASD cases showed a
relative hypomethylation compared with controls, and mostly
changed from a hypermethylated state to an intermediate state
(Beta-values from 30 to 60%; Supplementary Figure 3). Regarding
genomic location, 544 DMCpGs located within 467 genes and 10
miRNA, whereas 156 DMCpGs were intergenic probes (41.5 kb
from the gene Transcription Starting Sites; Figure 1). We searched
for convergence between the detected genes and core ASD-
associated genes compiled in SFARI and AutismKb databases
(n=486 genes), and found 32 genes (6.5%; Supplementary Table 5).
Although most DMCpGs were case specific, we found 20
present in two or more ASD patients. Rare SNPs at the CG position
(meSNPs) had been described at 9 (45%) of these sites (dbSNP137
and 1000G MAFo0.005), so we assumed the SNPs were the cause
of the DMCpG. Validation and segregation analysis of the
remaining DMCpGs (n= 11) revealed that all were also rare
single-nucleotide variants (meSNVs) inherited from healthy
progenitors (Supplementary Table 2).
Figure 1. Pipeline followed for the differential methylation analyses with detailed filtering criteria. For the first two comparisons (DM1 and
DM2), we established a P-value threshold o0.01, whereas in the third comparison (DM3) we searched for rare methylation alterations in a
large control cohort (frequency o0.005). We obtained 700 DMCpGs, 156 intergenic probes and 544 of them encompassing 467 genes and 10
miRNA. We selected for further analyses the DMCpGs found in more than one case, including the dbGAP study (accession=phs000619), the
differentially methylated regions, and the DMCpGs associated with significant cis-acting expression changes. Further studies with patients and
controls were performed, for which some public accession data were added to the cohorts (data not added). Venn-diagram: correlation data
between two normalization methods showing high concordance. ASD, autism spectrum disorder; C, controls; DM, differential methylation
analysis; DMCpGs, differentially methylated CpGs; F, females; M, males.
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We also found five DMRs in four different patients (one patient
had two DMRs). Methylation levels were validated, and we
discarded underlying genetic changes by dosage analysis with
MLPA probes in the region and by sequencing of the flanking
intervals. These clustered epimutations were inherited in three
cases, two from the father and one from the mother, with identical
degree and extension in the parental samples (Table 1 and
Supplementary Figures 4–7). A search for DMRs with less-stringent
methylation differences using the COMB-P algorithm revealed six
additional regions, but they were also found altered in several
controls and then not considered as ASD specific.
Transcriptional consequences of DMCpGs
Out of the 476 DMCpGs altered in any of the 29 samples with
blood transcriptomic data by RNAseq, we studied expression
changes of nearby genes that were expressed in blood (n= 630).
We observed a strong correlation (Z-score42) with expression
changes of flanking genes in 7.6% of the loci harboring DMCpGs.
Validation and segregation analysis of the 15 DMCpGs outside
DMRs revealed that all contained rare inherited meSNVs
(Supplementary Table 2, Supplementary Figure 8). Interestingly,
a methylation alteration in the promoter of RNF166 led to a
transcriptional alteration of three flanking genes (Figure 2).
Regarding the rare meSNVs present in more than one patient, a
significant overexpression of the flanking gene(s) was observed in
four cases and a downregulation in one. The meSNV causing
hypomethylation within GALNT5 correlated with overexpression
of the nearby ERMN gene (Table 1 and Figure 3) in one of the
cases (ASD_5). Finally, RNAseq also revealed significant changes
of the expression levels of flanking genes in 4/5 of the DMRs
(Figure 4).
Rare meSNVs associated to ASD
We first used methylomic (Illumina 27k, Illumina) data from
blood DNA of 415 ASD cases and 405 controls as a replication
cohort. Only 17 (2.4%) of the 700 DMCpGs were covered by this
array. Relative hypomethylation at cg25781162 (ABCG5), caused by
an inherited meSNP in one of our probands, was also detected in
another ASD patient, and absent in controls (Table 1).
To determine whether a selected set of rare meSNVs (found in
more than one ASD patient and/or associated with transcriptional
effects) were statistically associated to ASD, we genotyped them
by Sequenom in an additional 394 ASD and 500 Spanish controls.
None of the variants were common in the Spanish control
population (MAFo0.002), discarding population-specific variants.
Significant association following multiple testing corrections (q-
valueo0.05) was found with five meSNVs (at the loci: GALNT5-
ERMN, USP24, METTL21C, PDE10A and DBT; Table 1). Considering all
the data for case–control analyses, six additional meSNVs
identified in a single or two ASD patient(s) were absent in all
the studied control samples (n= 935–1713; Table 1).
We also used pyrosequencing in another cohort of ASD patients
(n= 75) to check whether three of the clustered DMRs were
present in more cases, but all resulted negative. Therefore, most of
Figure 2. Heterozygous meSNV associated with overexpression of several regional genes at 16q24.3. (a) Beta values across the region for the
patient (green), the rest of the patients (red), the age-paired (blue) and the Spanish and GEO (GSE:40279; purple) controls sets. Diagram under
the graphs shows the genes in the region, 450k array probes, the DHSs and chromatin domains in the region. (b) Sanger sequence for the
DMCpG showed a paternally inherited meSNV (G4A). (c) Expression levels showed overexpression of RNF166 and MVD, and a tendency in
CTU2 (d) correlation for methylation values and expression for the genes for all ASD samples. ASD, autism spectrum disorder; C, controls; DHSs,
DNAseI hypersensitive sites.
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these DMRs were patient specific and absent in controls (n= 757),
except for one present in 3 of the 757 controls. Taken together,
these patient-specific meSNVs and DMRs are still good candidates
that cannot be excluded from being associated with ASD risk,
although replication in larger data sets would be required.
Deleterious mutations in ERMN associated to ASD
To identify other putative genetic mutations in some genes whose
methylation and expression changes showed association with
ASD disease, we performed targeted resequencing of the coding
regions of 5 selected genes (ERMN, STX16, SMG7-AS1, PIK3CD and
ZCCHC9). We completed the screening in additional 279 ASD
patients and 105 Spanish controls, used to exclude population-
specific variants. No loss-of-function mutations were identified in
any of the genes in the ASD cohort, but deleterious missense rare
variants were detected. Mutations in ERMN were identified in
three unrelated ASD patients, one in two cases (c.830G4A/R277Q)
and the second in one case (c.823 T4G/S275A) (Supplementary
Table 6). We also reanalyzed 931 exomes of ASD patients
(previously reported in O’Roak et al.53 and De Rubeis et al.54)
available from dbGAP and the EXAC repository data to define the
mutation load. We identified five additional ASD cases harboring
the same R277Q mutation and four additional deleterious
mutations in ASD patients (Figure 3 and Supplementary Table
6). In the EXAC repository, a total of 327 predicted pathogenic
mutations could be found. By comparison, a significant increase in
the mutation load of ERMN in ASD with respect to controls was
observed (P-value = 0.046), which is much more significant if we
exclude three population-specific variants (P-value = 7.97E− 05).
The finding of a higher mutation burden in ASD patients, along
with a positive association with a single meSNV at this locus and
the overexpression in carriers of the meSNV, strongly support that
ERMN is implicated in ASD. No significant mutation burden was
identified in any of the other screened genes in ASD patients.
General gene ontology analysis
Gene onthology analysis for the total amount of genes (n= 467)
revealed six significantly (P-valueo0.05) enriched KEGG pathways
(DavidGO; Supplementary Table 7): axon guidance (n= 10 genes),
PIP metabolism (n= 5 genes), chemokine signaling (n= 10 genes),
focal adhesion (n= 12 genes), adherence (n= 6 genes) and tight
junctions (n= 8 genes). Regarding the biological function enrich-
ment annotation chart (CPDB database), we found enrichment in
functions such as nervous system development (n= 73 genes),
neuron development (n= 30), synaptic transmission (n= 28), cell
death (n= 59 genes) and immune response (n= 18 genes). In
addition, when analyzing all the significant associated regions and
Figure 3. Example of a DMCpGs present in more than one case with associated effects on gene expression. (a) Hypomethylation in
cg05777410 correlated with ERMN overexpression. Beta values for the region showing two individuals (ASD_1 and ASD_5) with DM at a single
site in the region, cg05777410; the rest of ASD patients (red), the age-paired (blue) and the Spanish and GEO (GSE:40279; purple) control sets
showed a similar pattern. The diagram under the graph shows the genomic context with the GALNT5 and ERMN genes, 450k array probes,
DNSs and chromatin domains. (b) Sanger sequence of the region in the ASD_5 trio showing a maternally inherited meSNV (C4T in
chr2:158162587) at cg05777410. (c) Quantitative RNAseq data for ERMN and GALNT5 transcripts showed a significant overexpression of the
ERMN gene in ASD_5, and ASD_33 compared with the rest of individuals. (d) Location of the deleterious mutations at the coding region of
Ermin, showing exclusively those detected in ASD patients. ASD, autism spectrum disorder; C, controls.
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the DMRs we found only AMPK signaling pathway significantly
enriched (CAMKK1 and PIK3CD).
DISCUSSION
With the main goal of identifying methylation aberrations as
testable epigenetic biomarkers for ASD, we have performed an
epigenome-wide association study in blood DNA in a selected
cohort of idiopathic ASD patients, and explored the functional
consequences on blood transcriptome of a subset. Although ASD
is mainly a disorder of neurodevelopment and there are genomic
regulatory regions with brain-specific epigenetic states, there is
evidence that blood cells can be used as proxies for epigenetic
state at the many regions whose epigenetic state is common to
multiple tissues.55 We used the 450k methylomic array containing
selected probes for ~ 1.7% of the estimated 28 million CpG sites of
the human genome. No systemic methylation alterations were
identified in this ASD population, as previously shown in other
studies of ASD using brain and blood DNA samples.19,56 Despite
the small size of our and the previously reported cohorts, the
combined data discarded common DMRs in the regions analyzed
shared by all ASD patients. In a similar manner to most genetic
variants currently associated to ASD, and considering the low-
recurrent nature of epigenetic events, low prevalent or individual-
specific epimutations would not be detected with this type of
group analyses.56 We then searched for individual-specific ASD-
related variants using a large number of controls (n= 757), both
age matched and adults. We considered that including many
controls with a wide age range would provide more power to
select ASD-related and significant changes without biased
comparisons. Although blood DNA methylation has been shown
to vary with aging, the changes are of small magnitude (10%
reduction on average) and affecting a small amount of the 450k
array probes (2.1–15%).26,57
A total of 700 DMCpGs in 467 genes were detected specifically
in the ASD cohort, 13 per patient on average. Interestingly, 83.85%
of these DMCpGs showed relative hypomethylation, in agreement
with previous reports showing global hypomethylation in blood of
ASD patients,58 although all clustered regions showed hyper-
methylation in ASD cases. The integrative study with blood
transcriptome allowed the identification of cis-acting gene
expression effects for 7.6% of the DMCpGs, more commonly
overexpression associated to hypomethylation. In support of their
potential pathogenic implications, 4.5% of the DMCpGs were also
found in ASD patients’ brain,21 whereas 6.5% of the genes were
ASD-related genes reported by mutation, copy number variant
and/or association analyses. Most of the isolated DMCpGs
identified were due to meSNVs, and were inherited in all tested
cases. The high proportion of meSNVs among DMCpGs was due,
at least in part, to the stringent filters applied to focus on the most
severe methylation changes (50% or more), expected with
mutations at CpG.30 Anyhow, heterozygous SNPs at CpGs are
clearly implicated in the allele-specific methylation events, being
an important class of cis-regulatory variants connecting genetics
to epigenetics.59 The expression changes related to meSNVs can
be due to the interference with trans-acting regulatory elements
of either the methylation alteration itself, the underlying sequence
variant or both factors together.
We identified and validated five DMRs in four ASD patients, with
cis-acting expression effects on neighboring genes documented in
four regions. Interestingly, all DMRs were inherited events also
found in one of the parents. This germline transmission of
epimutations could be explained by reprogramming evasion
mechanisms60 or by undetected cis-acting genetic or genomic
mutations affecting methylation of the region.61 The hypermethy-
lation of the SMG7-antisense and SMG7 promoter region was
paradoxically associated with SMG7 overexpression in a single
patient (Supplementary Figure 6). SMG7 is involved in nonsense-
mediated mRNA decay regulation, a pathway that has also been
previously implicated in ASD and related syndromes.62 Other
DMRs in single-ASD patients affected the regulation of genes
involved in the development and function of the nervous system
(PHACTR1,63 PIK3CD64 and PKD165). Methylation deregulation of
PIK3CD has been shown in ASD brain,21 and the gene was
associated to schizophrenia.66 Similarly, PKD1 expression was
found downregulated in ASD67 and also associated to neuropsy-
chiatric diseases, including ASD.68
Through an extended case/control association study, we
identified six rare meSNVs significantly associated with ASD. The
most significant association was detected with a CpG located
Figure 4. Diagram showing the region and expression for ZCCHC9 detected DMR. (a) Diagram for the region with 13 CpGs altered located in
ZCCHC9 promoter (pointed with an arrow). The diagram shows the gene location, the 450k array probes, the DNAseI hypersensitive clusters,
and chromatin domain regions. ASD_13 shows increased methylation levels. (b) Expression for all ASD patients for the region. ASD_13 shows
a downregulation for the gene. ASD, autism spectrum disorder; C, controls; DMRs, differentially methylated regions.
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close to an enhancer and DNAse hypersensitive site between the
GALNT5 and ERMN genes (chr2q24.1). Although GALNT5 is not
expressed in blood, ERMN was found overexpressed in one patient
presenting the rare meSNV. Moreover, by targeted resequencing,
we found that ERMN showed a higher load of rare damaging
mutations in ASD patients. ERMN encodes an oligodendroglia-
specific cytoskeletal protein (Ermin) involved in myelination,
upregulated during active myelination periods in rat axons.69
The moesin/actin-binding domain has been shown to be
essential for the ability of Ermin to promote arborization and
morphological changes in cultured COS-7 cells.70 Correct
myelination is crucial in ASD and mood disorders.71–73 Interest-
ingly, ERMN is located within the boundaries of the AUTS5 locus,
which has repeatedly shown linkage to autism,74 language
impairment75 and IQ.76 Moreover, deletions including ERMN have
been reported in patients with developmental delay and impaired
communication,77 and ERMN expression is lower in epileptic
patients brains suggesting also a role in the epileptogenic
process.70 In fact, gain of function through overexpression and
loss of function through deleterious mutations would suggest
delicate gene dosage equilibrium.
The other five rare meSNVs significantly associated are also
strong ASD candidates affecting relevant genes. (1) USP24,
encodes a deubiquitinating enzyme that has been associated to
Parkinson’s physiopathology.78 (2) PDE10A, a paternally imprinted
gene79 highly expressed in specific brain regions, encodes a cyclic
nucleotide phosphodiesterase that regulates signal transduction;
the gene was found disrupted by a chromosomal translocation in
a patient with neurodevelopmental disorder and was proposed as
a therapeutic target for cognitive impairment in schizophrenia.80
(3) METTL21C, encoding a lysine methyltransferase for non-histone
proteins, regulates molecular chaperones related to neuroinflama-
tion, such as the Hsp70 found altered in the plasma of some ASD
patients.81 (4) The meSNV on TRM13 associated with over-
expression of the nearby DBT, coding for the transacylase E2
subunit of the branched-chain alpha-keto-acid dehydrogenase
complex mutated in patients with autosomal recessive urine
disease82 and ASD with epilepsy phenotype.83 (5) A meSNV
showing nominal association was associated with overexpression
of STX16, which is involved in synaptic vesicle transport, a pathway
known to be impaired in ASD.84
The remaining rare DMCpGs/meSNVs found in single or few
ASD patients need additional studies in larger data sets to confirm
a potential association with the phenotype. Some of them have
been related to ASD by point mutations (C15orf62/DNAJC17 and
ADAP1), linkage studies (TLE3), aberrant brain expression (PRCD,
LCP1, RXRB and SETD1A)67 and copy number variants (n= 11
genes). Other genes were involved in relevant functions as neuron
differentiation (SERPINF1, TCF12 and KAL1), neuron signaling
(C1QL3) and ubiquitinization (DNAJC17 and RAB40B). Pathways
enrichment analysis showed significant results in mechanisms
previously related to ASD including axonogenesis,71 cell
adhesion,85 immune chemokine signaling86 and PIP signaling.87
In summary, this epigenome-wide association study integrated
with transcriptome in blood samples revealed significant associa-
tion of ASD with hypomethylation caused by rare meSNVs at
several loci, as well as a few clustered epimutations in single-ASD
patients. Thus, methylation alterations detectable in blood DNA,
due to either genetic or epigenetic defects, can contribute to ASD
susceptibility. Given that most probands harbor more than one
methylation variant and all of them are inherited from unaffected
parents, their contribution to the phenotype is more likely to be
additive, in an oligogenic manner. The study also reveals that
ERMN is a strong ASD susceptibility gene that can be altered by
both rare meSNV and mutations. Additional studies of genome-
wide DNA methylation in larger ASD cohorts, integrated with
genomic, transcriptomic, proteomic as well as the phenotypic
data, are needed to further unravel the complex etiopathogeny of
this multifactorial disorder.
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